logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Kaoru Tsuchiya

japanese red cross musashino hospital
H指数:38
被引数:6,248

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds

FIB-4指数和FIB-3指数对慢性肝病中晚期肝纤维化的诊断准确性及年龄特异性阈值

Journal of Clinical Medicine
IF2.9
2026-03-030
OAAI
Shohei Kimura; Nobuharu Tamaki; Mayu Higuchi; Takuya Shima; Mina Taguchi; Yudai Yamazaki; Risa Seike; Naoki Uchihara; Yuki Tanaka; Ryohei Kobayashi; Junko Yagita; Yuka Kasano; Yasuyuki Komiyama; Kenta Takaura; Hitomi Takada; Shohei Tanaka; Chiaki Maeyashiki; Yutaka Yasui; Hiroyuki Nakanishi; Kaoru Tsuchiya; Namiki Izumi; Masayuki Kurosaki
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT

阿替利珠单抗联合贝伐珠单抗用于不适合TACE治疗的超出Up-To-7标准的中间阶段肝癌：REPLACEMENT研究的最终分析

Liver International
IF5.2
2025-11-030
OAAI
Kazuomi Ueshima; Kaoru Tsuchiya; Tatsuya Yamashita; Shigeo Shimose; Kazushi Numata; Yuzo Kodama; Shinji Itoh; Yasuhito Tanaka; Hidekatsu Kuroda; Kazuyoshi Ohkawa; Teiji Kuzuya; Masafumi Ikeda; Youhei Kooka; Hiroshi Aikata; Atsushi Hiraoka; Michihisa Moriguchi; Ryosuke Tateishi; Sadahisa Ogasawara; Kouji Yamamoto; Masatoshi Kudo
Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older

射频消融在80岁及以上肝细胞癌患者中的临床疗效

PLOS ONE
IF2.6
2025-10-140
PRE
Takaura, Kenta; Tsuchiya, Kaoru; Taguchi, Mina; Tokunaga, Yuzuki; Uchihara, Naoki; Kimura, Shohei; Tanaka, Yuuki; Yagita, Junko; Miyamoto, Haruka; Keitoku, Taisei; Okada, Risa; Higuchi, Mayu; Tanaka, Shohei; Maeyashiki, Chiaki; Tamaki, Nobuharu; Yasui, Yutaka; Takahashi, Yuka; Nakanishi, Hiroyuki; Izumi, Namiki; Kurosaki, Masayuki
Effect of Pemafibrate on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Multicenter Study

Pemafibrate对代谢功能障碍相关脂肪性肝病的影响：一项全国多中心研究

JGH OPEN
IF0
2025-09-090
OAAI
Komiyama, Yasuyuki; Tamaki, Nobuharu; Tsuji, Keiji; Mori, Nami; Mashiba, Toshie; Ochi, Hironori; Kobashi, Haruhiko; Ogawa, Chikara; Nonogi, Michiko; Yoshida, Hideo; Akahane, Takehiro; Kondo, Masahiko; Kasai, Toyotaka; Fujii, Hideki; Uchida, Yasushi; Arai, Hirotaka; Tsuchiya, Kaoru; Izumi, Namiki; Kurosaki, Masayuki
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

不可切除的肝细胞癌接受阿替利珠单抗联合贝伐珠单抗治疗后的三年总生存率

Hepatology International
IF6.1
2025-08-280
PRE
Masatsugu Ohara; Goki Suda; Risako Kohya; Yutaka Yasui; Kaoru Tsuchiya; Masayuki Kurosaki; Joji Tani; Shinya Maekawa; Nobuyuki Enomoto; Makoto Chuma; Manabu Morimoto; Shun Kaneko; Mina Nakagawa; Yasuhiro Asahina; Atsumasa Komori; Yuki Kugiyama; Masaru Baba; Akihisa Nakamura; Jun Ito; Ren Yamada; Shunichi Hosoda; Yoshiya Yamamoto; Sonoe Yoshida; Takuya Sho; Takashi Sasaki; Tomoka Yoda; Akimitsu Meno; Naohiro Yasuura; Qingjie Fu; Zijian Yang; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Koji Ogawa; Naoya Sakamoto
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment

《柳叶刀》关于应对全球肝细胞癌负担的委员会报告：从预防到治疗的综合策略

lancet
IF0
2025-07-280
PRE
Stephen Lam Chan; Hui-Chuan Sun; Yang Xu; Hongmei Zeng; Hashem B El-Serag; Jeong Min Lee; Myron E Schwartz; Richard S Finn; Jinsil Seong; Xin Wei Wang; Valérie Paradis; Ghassan K Abou-Alfa; Lorenza Rimassa; Jia-Horng Kao; Bo-Heng Zhang; Josep M Llovet; Jordi Bruix; Terry Cheuk-Fung Yip; Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Landon L Chan; Man-Qi Liu; Qiang Gao; Feng Shen; Robin Kate Kelley; Ann-Lii Cheng; Masayuki Kurosaki; Hidenori Toyoda; Wei-Xia Chen; Takamichi Murakami; Ping Liang; Jessica Zucman-Rossi; Yasunori Minami; Shiro Miyayama; Kui Wang; Kwan Man; Kiyoshi Hasegawa; Qiu Li; Kaoru Tsuchiya; Li Xu; Valerie Chew; Pierce Chow; Yujin Hoshida; Amaia Lujambio; Irene Oi-Lin Ng; Michiie Sakamoto; Young Nyun Park; Thomas Yau; Masatoshi Kudo; Jia Fan; Jian Zhou
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
BMC CANCER
IF3.4
2025-03-110
OAAI
Kodama, Yoshihisa; Ueshima, Kazuomi; Moriguchi, Michihisa; Inaba, Yoshitaka; Yamashita, Tatsuya; Iwamoto, Hideki; Ueno, Makoto; Ogasawara, Sadahisa; Kuzuya, Teiji; Kodama, Takahiro; Sato, Yozo; Tada, Toshifumi; Tsuchiya, Kaoru; Nishiofuku, Hideyuki; Yamakado, Koichiro; Sone, Miyuki; Ikeda, Masafumi; Takehara, Tetsuo; Hamano, Tetsutaro; Kudo, Masatoshi
Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group
HEPATOLOGY RESEARCH
IF3.4
2025-02-190
PRE
Tsuji, Keiji; Tamaki, Nobuharu; Kurosaki, Masayuki; Mori, Nami; Takaki, Shintaro; Ohya, Kazuki; Mashiba, Toshie; Ochi, Hironori; Kobashi, Haruhiko; Ogawa, Chikara; Nonogi, Michiko; Yoshida, Hideo; Akahane, Takehiro; Kondo, Masahiko; Kasai, Toyotaka; Fujii, Hideki; Uchida, Yasushi; Arai, Hirotaka; Tsuchiya, Kaoru; Izumi, Namiki
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma

在不可切除的肝细胞癌中，先前使用免疫检查点抑制剂进展后对durvalumab联合tremelimumab的治疗反应

INVESTIGATIONAL NEW DRUGS
IF2.7
2024-08-303
PRE
Mori, Nami; Tamaki, Nobuharu; Takaki, Shintaro; Tsuji, Keiji; Tada, Toshifumi; Nakamura, Shinichiro; Ochi, Hironori; Mashiba, Toshie; Doisaki, Masao; Marusawa, Hiroyuki; Kobashi, Haruhiko; Fujii, Hideki; Ogawa, Chikara; Nonogi, Michiko; Arai, Hirotaka; Uchida, Yasushi; Urawa, Naohito; Narita, Ryoichi; Akahane, Takehiro; Kondo, Masahiko; Yasui, Yutaka; Tsuchiya, Kaoru; Izumi, Namiki; Kurosaki, Masayuki
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
INVESTIGATIONAL NEW DRUGS
IF2.7
2024-06-060
OAAI
Kobayashi, Kazufumi; Ogasawara, Sadahisa; Itobayashi, Ei; Okubo, Tomomi; Itokawa, Norio; Nakamura, Kazuyoshi; Moriguchi, Michihisa; Watanabe, Shunji; Ikeda, Masafumi; Kuroda, Hidekatsu; Kawaoka, Tomokazu; Hiraoka, Atsushi; Yasui, Yutaka; Kuzuya, Teiji; Sato, Rui; Kanzaki, Hiroaki; Koroki, Keisuke; Inoue, Masanori; Nakamura, Masato; Kiyono, Soichiro; Kanogawa, Naoya; Kondo, Takayuki; Nakamoto, Shingo; Ozawa, Yoshihito; Tsuchiya, Kaoru; Atsukawa, Masanori; Aikata, Hiroshi; Aramaki, Takeshi; Oka, Shiro; Morimoto, Naoki; Kurosaki, Masayuki; Itoh, Yoshito; Izumi, Namiki; Kato, Naoya
Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
IF3.4
2024-03-175
PRE
Suzuki, Keito; Yasui, Yutaka; Tsuchiya, Kaoru; Matsumoto, Hiroaki; Yamazaki, Yudai; Uchihara, Naoki; Tanaka, Yuki; Miyamoto, Haruka; Yamada-Shimizu, Michiko; Keitoku, Taisei; Okada, Risa; Higuchi, Mayu; Takaura, Kenta; Tanaka, Shohei; Maeyashiki, Chiaki; Tamaki, Nobuharu; Nakanishi, Hiroyuki; Takahashi, Yuka; Asahina, Yasuhiro; Okamoto, Ryuichi; Kurosaki, Masayuki; Izumi, Namiki
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease

代谢功能障碍相关性脂肪性肝病与非酒精性脂肪性肝病的一致性

HEPATOLOGY RESEARCH
IF3.4
2024-01-1716
PRE
Suzuki, Keito; Tamaki, Nobuharu; Kurosaki, Masayuki; Takahashi, Yuka; Yamazaki, Yudai; Uchihara, Naoki; Tanaka, Yuki; Miyamoto, Haruka; Yamada, Michiko; Keitoku, Taisei; Okada, Risa; Higuchi, Mayu; Takaura, Kenta; Tanaka, Shohei; Maeyashiki, Chiaki; Yasui, Yutaka; Tsuchiya, Kaoru; Nakanishi, Hiroyuki; Izumi, Namiki
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
LIVER CANCER
IF9.1
2023-11-282
OAAI
Kudo, Masatoshi; Tsuchiya, Kaoru; Shao, Yu-Yun; Finn, Richard S.; Galle, Peter R.; Ducreux, Michel; Cheng, Ann-Lii; Yamashita, Tatsuya; Koga, Hironori; Take, Ryosuke; Yamada, Kyoko; Asakawa, Takashi; Nakagawa, Yuki; Ikeda, Masafumi
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
INVESTIGATIONAL NEW DRUGS
IF2.7
2023-03-3011
PRE
Takaki, Shintaro; Kurosaki, Masayuki; Mori, Nami; Tsuji, Keiji; Ochi, Hironori; Marusawa, Hiroyuki; Nakamura, Shinichiro; Tada, Toshifumi; Narita, Ryoichi; Uchida, Yasushi; Akahane, Takehiro; Kondo, Masahiko; Kusakabe, Atsunori; Furuta, Koichiro; Kobashi, Haruhiko; Arai, Hirotaka; Nonogi, Michiko; Tamada, Takashi; Hasebe, Chitomi; Ogawa, Chikara; Sato, Takashi; Tamaki, Nobuharu; Yasui, Yutaka; Tsuchiya, Kaoru; Izumi, Namiki

研究方向

暂未获取到该数据
N
Namiki Izumi
H 指数:79论文数:656被引数:2.9万
M
Masayuki Kurosaki
H 指数:60论文数:696被引数:1.6万
Yutaka Yasui 封面图
Yutaka Yasui
H 指数:78论文数:548被引数:2.5万
N
Nobuharu Tamaki
H 指数:47论文数:334被引数:7,070
H
Hiroyuki Nakanishi
H 指数:40论文数:297被引数:5,787
J
Jun Itakura
H 指数:42论文数:252被引数:5,992
Y
Yuka Takahashi
H 指数:37论文数:351被引数:4,021
Y
Yasuhiro Asahina
H 指数:43论文数:250被引数:7,456
K
Kenta Takaura
H 指数:22论文数:105被引数:1,401
M
Mayu Higuchi
H 指数:23论文数:129被引数:1,434